Masimo to Present in Stifel 2024 Healthcare Conference
Masimo (NASDAQ: MASI) has announced its participation in the upcoming Stifel 2024 Healthcare Conference. The company's management will present on Monday, November 18, 2024 at 11:30 a.m. Eastern Time. Interested parties can access a live webcast of the presentation through Masimo's website. A replay option will be available after the live presentation concludes.
Masimo (NASDAQ: MASI) ha annunciato la sua partecipazione alla prossima Stifel 2024 Healthcare Conference. Il management dell'azienda presenterà il lunedì 18 novembre 2024 alle 11:30 ora orientale. Le parti interessate possono accedere a una diretta della presentazione attraverso il sito web di Masimo. Un'opzione di replay sarà disponibile dopo la conclusione della presentazione dal vivo.
Masimo (NASDAQ: MASI) ha anunciado su participación en la próxima Stifel 2024 Healthcare Conference. La dirección de la empresa presentará el lunes 18 de noviembre de 2024 a las 11:30 a.m. Hora del Este. Las partes interesadas pueden acceder a una transmisión en vivo de la presentación a través del sitio web de Masimo. Se estará disponible una opción de repetición después de que concluya la presentación en vivo.
Masimo (NASDAQ: MASI)는 다가오는 Stifel 2024 Healthcare Conference에 참여할 것이라고 발표했습니다. 회사 경영진은 2024년 11월 18일 월요일 오전 11시 30분 동부 표준시(EST)에 발표를 할 예정입니다. 관심이 있는 분들은 Masimo 웹사이트를 통해 발표의 생중계를 시청할 수 있습니다. 생방송 발표 후 재생 옵션이 제공될 예정입니다.
Masimo (NASDAQ: MASI) a annoncé sa participation à la prochaine Stifel 2024 Healthcare Conference. La direction de l'entreprise présentera le lundi 18 novembre 2024 à 11h30, heure de l'Est. Les personnes intéressées peuvent accéder à une diffusion en direct de la présentation via le site web de Masimo. Une option de rediffusion sera disponible après la conclusion de la présentation en direct.
Masimo (NASDAQ: MASI) hat seine Teilnahme an der bevorstehenden Stifel 2024 Healthcare Conference angekündigt. Das Management des Unternehmens wird am Montag, den 18. November 2024 um 11:30 Uhr Eastern Time präsentieren. Interessierte Parteien können die Live-Übertragung der Präsentation über die Website von Masimo abrufen. Eine Wiederholungsoption wird nach Abschluss der Live-Präsentation zur Verfügung stehen.
- None.
- None.
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bowers & Wilkins, Denon, Marantz, and Polk Audio. Our mission is to improve life, improve patient outcomes, and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.1 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,2 improve CCHD screening in newborns,3 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.4-7 Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,8 and is the primary pulse oximetry at all 10 top
RPVi has not received FDA 510(k) clearance and is not available for sale in
References
- Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
- Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
- Taenzer A et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.
- Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
- McGrath S et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
- McGrath S et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14 Mar.
- Estimate: Masimo data on file.
- https://www.newsweek.com/rankings/worlds-best-hospitals-2024/united-states
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI and ORI are trademarks or registered trademarks of Masimo Corporation
View source version on businesswire.com: https://www.businesswire.com/news/home/20241113026086/en/
Investor Contact: Eli Kammerman
(949) 297-7077
ekammerman@masimo.com
Media Contact: Evan Lamb
(949) 396-3376
elamb@masimo.com
Source: Masimo
FAQ
When is Masimo (MASI) presenting at the Stifel 2024 Healthcare Conference?
How can I watch Masimo's (MASI) presentation at the Stifel 2024 Healthcare Conference?
Will there be a replay available of Masimo's (MASI) Stifel 2024 Healthcare Conference presentation?